华西医学

华西医学

类风湿关节炎与抑郁症的认识现状及展望

查看全文

类风湿关节炎患者合并抑郁症的发病率较高,合并抑郁症增加医疗费用,降低药物疗效,降低用药依从性,增加并发症发病率,影响类风湿关节炎疾病进展。临床工作常常忽视抑郁对类风湿关节炎的影响。近年来的研究发现抑郁与免疫性疾病在发病机制上的相关性,抑郁症从影响炎症反应的激活以及延长、促进炎症因子的释放等方面增加免疫性疾病的患病风险。该文就抑郁与类风湿关节炎的相关性研究进展进行综述。

The incidence of depression in patients with rheumatoid arthritis is higher. The concomitant depression will increase medical expense, reduce drug efficacy, lower its compliance, increase the incidence of complication, and affect the cure of rheumatoid arthritis. The influence of depression to rheumatoid arthritis is usually ignored in clinical work. In recent years, the pertinence between depression and immune disease in pathogenesis is found in research: depression will increase the risk of immune diseases in activate inflammation as well as extend and promote the release of inflammatory factors. This article reviews research progress of correlation between depression and rheumatoid arthritis.

关键词: 类风湿关节炎; 抑郁症; 抗肿瘤坏死因子-α

Key words: Rheumatoid arthritis; Depression; Antitumor necrosis factor-α

引用本文: 任艳, 尹耕. 类风湿关节炎与抑郁症的认识现状及展望. 华西医学, 2018, 33(12): 1554-1557. doi: 10.7507/1002-0179.201808050 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Joyce AT, Smith P, Khandker R, et al. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol, 2009, 36(4): 743-752.
2. Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum, 2014, 44(2): 123-130.
3. Lok EY, Mok CC, Cheng CW, et al. Prevalence and determinants of psychiatric disorders in patients with rheumatoid arthritis. Psychosomatics, 2010, 51(4): 338-338.e8.
4. Matcham F, Rayner L, Steer S, et al. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology, 2013, 52(12): 2136-2148.
5. 杨春军, 王君颖, 孙春艳, 等. 我国类风湿关节炎患者抑郁患病率的 Meta 分析. 中华风湿病学杂志, 2015, 19(10): 662-668.
6. Andersson NW, Gustafsson LN, Okkels N, et al. Depression and the risk of autoimmune disease: a nationally representative, prospective longitudinal study. Psychol Med, 2015, 45(16): 3559-3569.
7. Tsai TY, Lu MC, Livneh H, et al. Does depression increase the risk of stroke in patients with rheumatoid arthritis? A population-based cohort study. BMJ Open, 2017, 7(4): e014233.
8. Matcham F, Ali S, Irving K, et al. Are depression and anxiety associated with disease activity in rheumatoid arthritis? A prospective study. BMC Musculoskelet Disord, 2016, 17: 155.
9. Kekow J, Moots R, Khandker R, et al. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology, 2011, 50(2): 401-409.
10. Xia Y, Yin R, Fu T, et al. Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis. Patient Prefer Adherence, 2016, 10: 735-742.
11. van den Bemt BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol, 1994, 8(4): 337-351.
12. Ofman JJ, Badamgarav E, Henning JM, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med, 2004, 117(3): 182-192.
13. Matcham F, Davies R, Hotopf M, et al. The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology Biologics Register. Rheumatology, 2018, 57(5): 835-843.
14. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull, 2014, 140(3): 774-815.
15. Lopresti AL, Maker GL, Hood SD, et al. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry, 2014, 48: 102-111.
16. Camara ML, Corrigan F, Jaehne EJ, et al. Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology, 2015, 40(2): 502-512.
17. Ortega A, Jadeja V, Zhou H. Postnatal development of lipopolysaccharide-induced inflammatory response in the brain. Inflamm Res, 2011, 60(2): 175-185.
18. Chen J, Song Y, Yang J, et al. The contribution of TNF-alpha in the amygdala to anxiety in mice with persistent inflammatory pain. Neurosci Lett, 2013, 541(29): 275-280.
19. Camara ML, Corrigan F, Jaehne EJ, et al. TNF-alpha and its receptors modulate complex behaviours and neurotrophins in transgenic mice. Psychoneuroendocrinology, 2013, 38(12): 3102-3114.
20. Abbott R, Whear R, Nikolaou V, et al. Tumour necrosis factor-alpha inhibitor therapy in chronic physical illness: a systematic review and meta-analysis of the effect on depression and anxiety. J Psychosom Res, 2015, 79(3): 175-184.
21. Barton GM. A calculated response: control of inflammation by the innate immune system. J Clin Invest, 2008, 118(2): 413-420.
22. Slavich GM, Cole SW. The emerging field of human social genomics. Clin Psychol Sci, 2013, 1(3): 331-348.
23. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol, 2005, 5(3): 243-251.
24. Anisman H, Matheson K. Stress, depression, and anhedonia: caveats concerning animal models. Neurosci Biobehav Rev, 2005, 29(4-5): 525-546.
25. Irwin MR, Cole SW. Reciprocal regulation of the neural and innate immune systems. Nat Rev Immunol, 2011, 11(9): 625-632.
26. Jarcho MR, Slavich GM, Tylova-Stein HA, et al. Dysregulated diurnal cortisol pattern is associated with glucocorticoid resistance in women with major depressive disorder. Biol Psychol, 2013, 93(1): 150-158.
27. O’donovan A, Hughes BM, Slavich GM, et al. Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain Behav Immun, 2010, 24(7): 1074-1077.